FujiFilm-backed genetic disorder drug developer EdiGene has secured $14.3m from investors including SBI Investment, SMBC Capital and Mizuho Capital.
EdiGene, a Japan-based developer of treatments for genetic disorders, raised ¥1.6bn ($14.3m) in series B funding on Wednesday, from investors including financial services firms SBI Group, Sumitomo Mitsui Banking Corporation and Mizuho Bank.
The firms, which invested through subsidiaries SBI Investment, SMBC Capital and Mizuho Capital respectively, were joined by University of Tokyo’s investment company UTokyo Innovation Platform, business development consultancy Fast Track Initiative, CareNet Group and unnamed existing investors.
Founded in 2016, EdiGene is developing therapeutic candidates for a…
